Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Gepubliceerd in:
1 Nederlandse hepatologie in historisch en toekomstig perspectief hoofdstuk lezen eerste hoofdstuk lezen

2009 | OriginalPaper | Hoofdstuk

11 Auto-immuunhepatitis en overlapsyndromen

Auteurs : Dr. B. van Hoek, Dr. C.M.J. van Nieuwkerk, S.V. Jarbandhan

Gepubliceerd in: Leverziekten

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

In dit hoofdstuk staat auto-immuunhepatitis (AIH) centraal. Er zijn echter patiënten die zich presenteren met diagnostische karakteristieken van meer dan een auto-immuunleverziekte: AIH, primaire scleroserende cholangitis (PSC), primaire biliaire cirrose (PBC) en auto-immuuncholangitis (AIC). Daarom worden ook de overlapsyndromen behandeld.
vorige hoofdstuk 10 Cholestatische leverziekten
volgende hoofdstuk 12 Niet-alcoholische steatohepatitis
Literatuur
1.
2.
Hoek B van. The spectrum of liver disease in systemic lupus erythematosus. Neth J Med 1996;48(6):244–253.PubMedCrossRef
3.
Kaw R, Gota C, Bennett A, Barnes D, Calabrese L. Lupus-related hepatitis: complication of lupus or autoimmune association? Case report and review of the literature. Dig Dis Sci 2006;51(4):813–818.PubMedCrossRef
4.
Alvarez F, Berg PA, Bianchi FB, et al. International Auto-immune Hepatitis Group Report: review of criteria for diagnosis of auto-immune hepatitis. J Hepatol 1999;31(5):929–938.PubMedCrossRef
5.
Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW. International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169–176.PubMedCrossRef
6.
Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008;48:1540–1548.PubMedCrossRef
7.
Czaja AJ. Auto-immune liver disease and rheumatic manifestations. Curr Opin Rheumatol 2007;19(1):74–80.PubMedCrossRef
8.
Gomez dlT, Florido Mancheno JI, Suarez d V, Rubio BS, Alvarez Chao MT. [Extrahepatic manifestations of type I auto-immune hepatitis]. Rev Clin Esp 2001; 201(6):363–364.CrossRef
9.
Czaja AJ, Manns MP. The validity and importance of subtypes in auto-immune hepatitis: a point of view. Am J Gastroenterol 1995;90(8):1206–1211.PubMed
10.
11.
Carpenter HA, Czaja AJ. The role of histologic evaluationin the diagnosis and management of auto-immune hepatitis and its variants. Clin Liver Dis 2002;6(3): 685–705.PubMedCrossRef
12.
13.
Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of auto-immune hepatitis.Clin Gastroenterol Hepatol 2008;6(4):379–388.PubMedCrossRef
14.
Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 auto-immune hepatitis. Clin Liver Dis 2002;6(3):419–437.CrossRef
15.
Lapierre P, Beland K, Alvarez F. Pathogenesis of autoimmune hepatitis: from break of tolerance to immunemediated hepatocyte apoptosis. Transl Res 2007;149(3): 107–113.PubMedCrossRef
16.
Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of auto-immune hepatitis. Clin Liver Dis 2002;6(3):439–449.CrossRef
17.
Montano Loza AJ, Czaja AJ. Current therapy for autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol 2007;4(4):202–214.PubMedCrossRef
18.
19.
Manns M, Woynarowski M, Kreisel W, Oren R, Rust C, Hultcrantz RW, Spengler U, Szalay F, Lohse AW, Färkkilä M, Bahr MJ, Proels M, Zuckerman E, Günther R. Budesonide 3 mg BID in combination with azathioprine as maintenance treatment of autoimmune hepatitis – final results of a large multicenter international trial. J Hepatol 2008;48(4):376A.
20.
Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002;37(4):441–447.PubMedCrossRef
21.
Czaja AJ. Treatment strategies in auto-immune hepatitis. Clin Liver Dis 2002;6(3):511–536.
22.
Czaja AJ. Evolving concepts in the diagnosis, pathogenesis and treatment of auto-immune hepatitis. Minerva Gastroenterol Dietol 2007;53(1):43–78.PubMed
23.
Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol 2000;32(1 Suppl):181–197.PubMedCrossRef
24.
Soloway RD, Hewlett AT. The medical treatment for auto-immune hepatitis through corticosteroid to new immunosuppressive agents: a concise review.Ann Hepatol 2007;6(4):204–207.PubMed
25.
Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of auto-immune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004;18(5):321–326.PubMed
26.
Dhawan A, Mieli-Vergani G. Mycophenolate mofetil – a new treatment for auto-immune hepatitis? J Hepatol 2000;33(3):480–481.PubMedCrossRef
27.
Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in auto-immune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33(3):371–375.PubMedCrossRef
28.
Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory auto-immune hepatitis. J Clin Gastroenterol 2004;38(9):805–809.PubMedCrossRef
29.
Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent auto-immune hepatitis. Gastroenterology 2000;119(5):1312–1316.PubMedCrossRef
30.
Manns MP, Vogel A. Auto-immune hepatitis, from mechanisms to therapy. Hepatology 2006;43(2 Suppl 1):S132–S144.CrossRef
31.
Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333(15):958–963.PubMedCrossRef
32.
Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I auto-immune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004;99(8):1510–1516.PubMedCrossRef
33.
Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 auto-immune hepatitis. Liver Int 2003;23(2):116–123.PubMedCrossRef
34.
Sandhu BS, Sanyal AJ. Pregnancy and liver disease. Gastroenterol Clin North Am 2003;32(1):407–436, ix.
35.
36.
Al Khalidi JA, Czaja AJ. Current concepts in the diagnosis, pathogenesis, and treatment of auto-immune hepatitis. Mayo Clin Proc 2001;76(12):1237–1252.CrossRef
37.
Boberg KM. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis 2002;6(3):635–647.PubMedCrossRef
38.
Gautam M, Cheruvattath R, Balan V. Recurrence of auto-immune liver disease after liver transplantation: a systematic review.Liver Transpl 2006;12(12):1813–1824.PubMedCrossRef
39.
Sanchez-Urdazpal L, Czaja AJ, Hoek B van, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992; 15(2):215–221.PubMedCrossRef
40.
Jain A, Pokharna R, Eghtesad B, et al. Steroid withdrawal under tacrolimus for primary biliary cirrhosis, primary sclerosing cholangitis and auto-immune hepatitis after liver transplantation and long-term survival. Transplant Proc 2002;34(5):1524–1525.PubMedCrossRef
41.
Prados E, Cuervas-Mons V, de la MM et al. Outcome of auto-immune hepatitis after liver transplantation. Transplantation 1998;66(12):1645–1650.PubMedCrossRef
42.
Vogel A, Heinrich E, Bahr MJ, et al. Long-term outcome of liver transplantation for auto-immune hepatitis. Clin Transplant 2004;18(1):62–69.PubMedCrossRef
43.
Schramm C, Bubenheim M, O’Grady JG, et al. Long term outcome of patients transplanted for autoimmune hepatitis – analysis of the European Liver Transplant Registry. J Hepatol 2008;48(Suppl 2):S47.CrossRef
44.
Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of auto-immune hepatitis to primary sclerosing cholangitis:A sequential syndrome. Hepatology 2002;36(6): 1393–1399.PubMedCrossRef
45.
Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosisauto-immune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28(2): 296–301.PubMedCrossRef
46.
Colombato LA, Alvarez F, Cote J, Huet PM. Auto-immune cholangiopathy: the result of consecutive primary biliary cirrhosis and auto-immune hepatitis? Gastroenterology 1994;107(6):1839–1843.PubMed
47.
Gregorio GV, Portmann B, Karani J, et al. Auto-immune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33(3):544–553.PubMedCrossRef
48.
49.
50.
51.
Durazzo M, Premoli A, Fagoonee S, Pellicano R. Overlap syndromes of auto-immune hepatitis: what is known so far. Dig Dis Sci 2003;48(3):423–430.PubMedCrossRef
52.
Gershwin ME. The natural history of primary biliary cirrhosis: of genes and cooperation. J Hepatol 2001; 35(3):412–415.PubMedCrossRef
53.
Geubel AP, Baggenstoss AH, Summerskill WH. Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome. Gastroenterology 1976;71(3):444–449.PubMed
54.
Kloppel G, Seifert G, Lindner H, Dammermann R, Sack HJ, Berg PA. Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis. Correlations of liver histology with mitochondrial antibodies of different specificity. Virchows Arch A Pathol Anat Histol 1977;373(2):143–160.PubMedCrossRef
55.
Czaja AJ. Frequency and nature of the variant syndromes of auto-immune liver disease. Hepatology 1998; 28(2):360–365.PubMedCrossRef
56.
Joshi S, Cauch-Dudek K, Wanless IR et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002;35(2):409–413.PubMedCrossRef
57.
Buuren HR van, Hoogstraten HJE van, Terkivatan T, Schalm SW, Vleggaar FP. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000;33(4):543–548.PubMedCrossRef
58.
El-Shabrawi M, Wilkinson ML, Portmann B et al. Primary sclerosing cholangitis in childhood. Gastroenterology 1987;92(5 Pt 1):1226–1235.PubMed
59.
McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG. Auto-immune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998;93(5):777–784.PubMedCrossRef
60.
Wilschanski M, Chait P, Wade JA, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology 1995;22(5):1415–1422.PubMed
61.
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000;31(6):1231–1238.PubMedCrossRef
62.
Czaja AJ, Santrach PJ, Breanndan MS. Shared genetic risk factors in auto-immune liver disease. Dig Dis Sci 2001;46(1):140–147.PubMedCrossRef
63.
Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated auto-immune hepatitis. J Hepatol 1992;14(2–3):325–331.PubMedCrossRef
64.
Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann Intern Med 1985;102(5):581–587.PubMedCrossRef
65.
Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992;16(3):707–714.PubMedCrossRef
66.
Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336(10): 691–695.PubMedCrossRef
67.
Mitchell SA, Bansi DS, Hunt N, Von BK, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121(4):900–907.PubMedCrossRef
68.
Stiehl A. Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis. Scand J Gastroenterol Suppl 1994;204:59–61.PubMedCrossRef
69.
Gohlke F, Lohse AW, Dienes HP, et al. Evidence for an overlap syndrome of auto–immune hepatitis and primary sclerosing cholangitis. J Hepatol 1996;24(6):699–705.PubMedCrossRef
70.
McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG. Auto-immune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998;93(5):777–784.PubMedCrossRef
71.
72.
Burak KW, Urbanski SJ, Swain MG. A case of coexisting primary biliary cirrhosis and primary sclerosing cholangitis: a new overlap of auto-immune liver diseases. Dig Dis Sci 2001;46(9):2043–2047.PubMedCrossRef
73.
Rubel LR, Seeff LB, Patel V. Primary biliary cirrhosisprimary sclerosing cholangitis overlap syndrome. Arch Pathol Lab Med 1984;108(5):360–361.PubMed
74.
Czaja AJ. Chronic active hepatitis: the challenge for a new nomenclature. Ann Intern Med 1993;119(6):510–517.PubMedCrossRef
75.
Brunner G, Klinge O. [A chronic destructive non-suppurative cholangitis-like disease picture with antinuclear antibodies (immunocholangitis)]. Dtsch Med Wochenschr 1987;112(38):1454–1458.PubMedCrossRef
76.
Miyakawa H, Tanaka A, Kikuchi K, et al. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology 2001;34(2):243–248.PubMedCrossRef
77.
Tsuneyama K, Van de Water J, van Thiel D., et al. Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody-negative primary biliary cirrhosis. Hepatology 1995;22(5):1440–1446.PubMed
78.
Michieletti P, Wanless IR, Katz A, et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of auto-immune cholangitis. Gut 1994;35(2):260–265.PubMedCentralPubMedCrossRef
79.
Taylor SL, Dean PJ, Riely CA. Primary auto-immune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am J Surg Pathol 1994;18(1):91–99.PubMedCrossRef
80.
Ben-Ari Z, Dhillon AP, Sherlock S. Auto-immune cholangiopathy: part of the spectrum of auto-immune chronic active hepatitis. Hepatology 1993;18(1):10–15.PubMedCrossRef
81.
Kim WR, Poterucha JJ, Jorgensen RA, et al. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology 1997;26(1):22–26.PubMedCrossRef
82.
Lacerda MA, Ludwig J, Dickson ER, Jorgensen RA, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol 1995;90(2): 247–249.PubMed
Metagegevens
Titel
11 Auto-immuunhepatitis en overlapsyndromen
Auteurs
Dr. B. van Hoek
Dr. C.M.J. van Nieuwkerk
S.V. Jarbandhan
Copyright
2009
Uitgeverij
Bohn Stafleu van Loghum
Boek
Leverziekten

Print ISBN: 978-90-313-7436-6

Elektronisch ISBN: 978-90-313-7437-3

Copyright: 2009

DOI
https://doi.org/10.1007/978-90-313-7437-3_11